CLINICAL TRIALS PROFILE FOR BLINATUMOMAB

All Clinical Trials for blinatumomab

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01207388 ↗	Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)	Completed	Amgen Research (Munich) GmbH	Phase 2	2010-11-01	The purpose of this study is to confirm whether the bispecific T cell engager blinatumomab (MT103) is effective, safe and tolerable in the treatment of ALL patients with minimal residual disease.
NCT01371630 ↗	Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Acute Lymphoblastic Leukemia	Recruiting	National Cancer Institute (NCI)	Phase 1/Phase 2	2011-08-26	This phase I/II trial studies the side effects and best dose of inotuzumab ozogamicin and to see how well it works when given together with combination chemotherapy in treating older patients with previously untreated acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH). Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers CalichDMH to kill them. Immunotherapy with monoclonal antibodies, such as blinatumomab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving inotuzumab ozogamicin together with combination chemotherapy may be a better treatment for acute lymphoblastic leukemia.
NCT01371630 ↗	Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Acute Lymphoblastic Leukemia	Recruiting	Pfizer	Phase 1/Phase 2	2011-08-26	This phase I/II trial studies the side effects and best dose of inotuzumab ozogamicin and to see how well it works when given together with combination chemotherapy in treating older patients with previously untreated acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH). Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers CalichDMH to kill them. Immunotherapy with monoclonal antibodies, such as blinatumomab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving inotuzumab ozogamicin together with combination chemotherapy may be a better treatment for acute lymphoblastic leukemia.
NCT01371630 ↗	Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Acute Lymphoblastic Leukemia	Recruiting	M.D. Anderson Cancer Center	Phase 1/Phase 2	2011-08-26	This phase I/II trial studies the side effects and best dose of inotuzumab ozogamicin and to see how well it works when given together with combination chemotherapy in treating older patients with previously untreated acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH). Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers CalichDMH to kill them. Immunotherapy with monoclonal antibodies, such as blinatumomab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving inotuzumab ozogamicin together with combination chemotherapy may be a better treatment for acute lymphoblastic leukemia.
NCT01471782 ↗	Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia	Completed	Amgen Research (Munich) GmbH	Phase 1/Phase 2	2012-01-01	The purpose of this study is to determine the dose of the bispecific T cell engager blinatumomab (MT103) in pediatric and adolescent patients with relapsed/refractory Acute Lymphoblastic Leukemia (ALL) and to assess whether this dose of blinatumomab is effective.

Clinical Trial Conditions for blinatumomab

Condition Name

Condition Name for blinatumomab
Intervention	Trials
Acute Lymphoblastic Leukemia	28
Leukemia	9
B-cell Acute Lymphoblastic Leukemia	9
B Acute Lymphoblastic Leukemia	7

Condition MeSH

Condition MeSH for blinatumomab
Intervention	Trials
Precursor Cell Lymphoblastic Leukemia-Lymphoma	94
Leukemia	69
Leukemia, Lymphoid	63
Burkitt Lymphoma	18

Clinical Trial Locations for blinatumomab

Trials by Country

Trials by Country for blinatumomab
Location	Trials
United States	407
China	83
Spain	39
Australia	33
Canada	30

Trials by US State

Trials by US State for blinatumomab
Location	Trials
Texas	31
California	22
Tennessee	16
New York	15
Ohio	14

Clinical Trial Progress for blinatumomab

Clinical Trial Phase

Clinical Trial Phase for blinatumomab
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	2
PHASE2	33

Clinical Trial Status

Clinical Trial Status for blinatumomab
Clinical Trial Phase	Trials
Recruiting	73
NOT_YET_RECRUITING	23
Not yet recruiting	14

Clinical Trial Sponsors for blinatumomab

Sponsor Name

Sponsor Name for blinatumomab
Sponsor	Trials
Amgen	49
National Cancer Institute (NCI)	17
M.D. Anderson Cancer Center	15

Sponsor Type

Sponsor Type for blinatumomab
Sponsor	Trials
Other	159
Industry	80
NIH	17

Blinatumomab: Clinical Trials, Market Analysis, and Future Projections

Last updated: February 20, 2026

Blinatumomab is a bispecific T-cell engager (BiTE) designed to target CD19 on B-cells and CD3 on T-cells. Approved for specific hematologic malignancies, it is under continuous clinical evaluation and market expansion.

Clinical Trials Overview

Approved Indications and Ongoing Trials

Blinatumomab received FDA approval in December 2014 for relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL). Its primary clinical studies focus on:

• Relapsed/Refractory ALL: Phase 2 studies confirmed overall response rates of approximately 40%, with complete remission in about 30%. These trials continue to evaluate long-term survival and relapse rates.
• Minimal Residual Disease (MRD) Positive ALL: Phase 3 trials demonstrate potential for blinatumomab to eradicate MRD, extending remission duration (FOCUS: NCT02126463, completed 2017).
• Adult Philadelphia Chromosome-Positive ALL: Randomized trials assess combining blinatumomab with tyrosine kinase inhibitors, showing promising efficacy.

In addition, investigational studies explore:

• Non-Hodgkin Lymphoma (NHL): Multiple phase 1/2 trials with varying responses.
• Combination therapies: Trials assess efficacy with agents like inotuzumab ozogamicin and immune checkpoint inhibitors.

Key Trial Data Summary

Trial Phase	Indication	Response Rate	Completion Year	Status
Phase 2	R/R B-cell ALL	40% ORR	2014	Approved
Phase 3	MRD-positive ALL	Significant MRD clearance	2017	Ongoing
Phase 1/2	NHL	Varies	Ongoing	Investigational

Safety and Efficacy

Common adverse events include cytokine release syndrome (CRS), neurotoxicity, and febrile neutropenia. Dose adjustments mitigate risks, and patient monitoring protocols improve safety profiles.

Market Analysis

Market Size and Growth Drivers

• Global Hematologic Malignancies Market: Valued at approximately USD 45 billion in 2022; expected to grow at a CAGR of 8% through 2030.
• Target Population: Limited to B-cell malignancies; estimated at 10,000-15,000 new relapsed/refractory ALL cases annually in the US and EU.
• Competitive Landscape: Blinatumomab competes with CAR-T therapies (e.g., tisagenlecleucel) and other monoclonal antibodies. CAR-T therapies are more expensive but increasingly adopted due to high response rates.

Revenue Trends

• 2022: Estimated global sales of USD 920 million.
• 2025: Projected to reach USD 1.2 billion, driven by expanded indications and physician adoption.
• Market Penetration: Currently, blinatumomab holds roughly 40% share of available immunotherapy options for relapsed ALL; competition pressure persists.

Market Challenges

• Cost: High manufacturing costs and treatment price (~USD 178,000 per cycle) limit access.
• Administration: Continuous infusion over four weeks complicates outpatient management.
• Safety Concerns: CRS and neurotoxicity necessitate specialized treatment centers.

Regulatory Landscape

• Approved regions: US, EU, Japan.
• Next steps: Trials in pediatric populations and additional malignancies seek approvals.

Future Projections

Market Expansion Opportunities

• First-line treatment: Trials suggest potential as front-line therapy in combination with chemotherapy.
• Broader indications: Non-Hodgkin lymphoma, chronic lymphocytic leukemia, and multiple myeloma are under investigation.
• Bi-specific T-cell engagers pipeline: Competes with other agents targeting similar pathways, like Mosunetuzumab and epcoritamab.

Challenges and Risks

• Adverse events: Management protocols are critical; increased safety bar may delay adoption.
• Pricing pressure: Healthcare systems seek cost-effective alternatives.
• Competitive landscape: Emerging CAR-T therapies and bispecific antibodies could erode market share.

Strategic Outlook

• Partnerships with biotech firms for combination regimens.
• Investment in patient-monitoring technologies for safety management.
• Expansion into pediatric markets contingent on trial success.

Key Takeaways

• Blinatumomab's clinical success is confined mainly to relapsed/refractory B-cell malignancies with ongoing trials expanding its potential uses.
• The drug's market is growing, driven by unmet needs in hematologic cancers, but faces challenges from safety concerns and high costs.
• Future growth depends on approval for broader indications, improved safety management, and competitive positioning against new therapies.

FAQs

1. What are the primary indications for blinatumomab?
Blinatumomab is approved for relapsed/refractory B-cell precursor acute lymphoblastic leukemia and MRD-positive ALL in adults.

2. How does blinatumomab compare with CAR-T therapies?
Blinatumomab is less costly and requires continuous infusion, whereas CAR-T therapies offer higher response rates but at increased cost and risk of severe side effects.

3. Are there approved uses of blinatumomab outside the US and EU?
Regulatory approval exists in Japan; other regions are evaluating clinical trial data to consider approval.

4. What are the significant safety concerns?
Cytokine release syndrome and neurotoxicity are key adverse events, requiring careful patient monitoring.

5. What is the outlook for blinatumomab’s future market penetration?
Expansion into first-line therapy and additional indications, alongside management improvements, could double its market share within five years.

---

References

[1] U.S. Food and Drug Administration. (2014). FDA approves Blinatumomab for certain types of leukemia.

[2] MarketWatch. (2022). Hematologic Malignancies Market Size.

[3] ClinicalTrials.gov. (2023). Trials involving blinatumomab.